With the FreeStyle Libre 14 day system, you can see what impacts your glucose.
Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
The MyFreeStyle program helps guide you through your first continuous glucose monitoring (CGM) experience.
Track your activities in the reader to unlock insights about what impacts your glucose levels1,2
Get 14 days of guided support that can help lower your A1c levels†3,4
Most commercially insured patients pay between $0 to $60 per month for FreeStyle Libre 2 or FreeStyle Libre 14 day sensors,II¶#5 and no more than $65 for a FreeStyle Libre 2 or FreeStyle Libre 14 day reader (at participating pharmacies).¶**††5 The systems include both the sensor and the reader.1,2
Make more informed decisions†6:
CGM automatically tracks your glucose levels day and night using a small sensor worn on the back of the upper arm and a monitor that lets you view your glucose§§ levels at any timeII II
Unlike a blood glucose monitor, which only gives you a current glucose reading, CGM shows additional insights into where your glucose level was, currently is, and where it’s headed
* or ♢Eligible patients will receive one (1) FreeStyle Libre 14 day sensor or one (1) FreeStyle Libre 2 sensor and reader at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is not available for patients with gestational diabetes. Only patients 18 and older are eligible to receive an offer for the FreeStyle Libre 14 day sensor, and patients 4 and older are eligible to receive an offer for the FreeStyle Libre 2 sensor and reader. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader cannot be re-sold, traded nor submitted to any third party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
†Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
‡Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
IIBased on prescription claims for commercially insured patients using the FreeStyle Libre 14 day system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
¶As a courtesy to its customers, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer’s providers are ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.
#Based on prescription claims for commercially insured patients using the FreeStyle Libre 2 system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
**Benefits for FreeStyle Libre 14 day sensors apply to two 14 day sensors per month. Benefits for FreeStyle Libre 14 day reader apply to one 14 day reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs, or residents of US territories and possessions, except Puerto Rico. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
††Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors per month. Benefits for FreeStyle Libre 2 reader apply to one FreeStyle Libre 2 reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
‡‡On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). (www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf) The Durable Medical Equipment Medicare Administrative Contractors (DME MAC) subsequently issued guidance on the IFC policies, including discussing that clinical indications for coverage in the therapeutic CGM LCD (Glucose Monitors, L33822) will not be enforced. See “CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised May 21, 2020.” (www.cgsmedicare.com/jc/pubs/news/2020/05/cope1733) As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third-party coverage of payment for our products or reimburse customers for claims that are denied by third-party payors.
§§Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours.
II IIGlucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or "LO" or "HI" message, or no current glucose reading.
References: 1. FreeStyle Libre 2 User’s Manual. 2. FreeStyle Libre 14 day User’s Manual. 3. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 4. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 5. Data on file. Abbott Diabetes Care. 6. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no 4. (March 2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393.
Abbott supports patient access to the FreeStyle Libre family of products through a variety of programs, including trial offers, that may reduce the out-of-pocket amounts that patients must pay. The actual amount that a patient may pay may vary or change based on factors such as the duration of the program, product insurance coverage status, state of residence, or other eligibility limitations. Abbott may modify, rescind, or revoke these programs at any time without notice.
ADC-12211 Ver 18.0 05/21
Indications and Important Safety Information
FreeStyle Libre 14 day system: The FreeStyle Libre 14 day Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions. The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.
WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre 14 day system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre 14 day system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) (or visit www.freestylelibre.us) for detailed indications for use and safety information. For full indications for use and safety information, see more here.
FreeStyle Libre 2 system: The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.*
WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit * www.freestylelibre.us for detailed indications for use and safety information.
*Please refer to www.freestylelibre.us for the indications and important safety information.
The product images are for illustrative purposes only.
The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-29111 Ver 6.0 04/21
For more information about COVID-19, please click here